Table 1. Synthesis of data from the included studies in this review.

No	Authors name	Study type	Objective	Conclusion
1	Calderone et al. 2022 [34]	Systematic review and meta-analysis	This study focused on age as a treatment variable to examine the effectiveness and safety of aspirin in people without overt cardiovascular disease.	Aspirin use was linked to a somewhat lower risk of major cardiovascular events and a neutral effect on all-cause mortality in people without overt cardiovascular disease but at the cost of a higher risk of major bleeding. Younger people may benefit from aspirin more significantly.
2	Judge et al. 2020 [35]	Meta-analysis	To look into the effect of aspirin for primary avoidance of cardiovascular events.	In 11 trials (157,054 individuals), aspirin has been linked to a higher chance of hemorrhagic stroke but not a statistically important reduction in nonfatal stroke. There was no statistically significant reduction in mortality risk linked with aspirin.
3	Patel and Baliga, 2020 [50]	Review	To examine the clinical data on the effectiveness of aspirin for individuals with diabetes mellitus and elderly people with good health.	The risks associated with bleeding outweighed the advantages of aspirin treatment in adults with diabetes who had never had cardiovascular disease. In addition, aspirin use in healthy elderly people increased the risk of severe hemorrhage rather than extending disability-free life expectancy.
3.	Bowman et al. 2019 [48]	Randomized controlled trial	To evaluate the effect of aspirin in patients suffering from diabetes mellitus.	Cardiovascular events are linked to an elevated risk in those with diabetes mellitus. The balance of advantages and risks for the prevention of first cardiovascular events in patients with diabetes is uncertain. The use of aspirin lowers the risk of occlusive vascular events but raises the risk of bleeding.
4.	McNeil et al. 2018 [39]	Randomized controlled trial	To analyze the scientific approach to ascertain the effect of aspirin on mortality from all causes in healthy elderly.	When elderly people were taking daily aspirin compared to those taking a placebo, they experienced higher all-cause mortality rates, which were mostly due to cancer-related deaths.
5	Guirguis-Blake et al. 2016 [36]	Review	The goal of this study was to evaluate a systematic study on aspirin's advantages in cardio-vascular event prevention at individual's age of 40 years or more.	Aspirin has a moderately positive effect on the primary prevention of cardiovascular disease when taken daily in doses of 100 mg or less. Older persons appear to gain benefits more relatively from myocardial infarction.
6	García Rodríguez et al. 2016 [43]	Review	To investigate the potential risk of bleeding for a long time from the use of low-dose aspirin.	Low-dose aspirin has similar risks for severe bleeding in real-world situations as it does in randomized studies. The use of low-dose aspirin in the prevention of cardiovascular events will be guided by these facts in clinical decisions.
7	ASPREE Investigator Group 2013 [38]	Randomized controlled trial	To determine if the potential risks of low-dose aspirin use in older, healthy people outweigh any possible primary preventive benefits.	Aspirin's potential to prolong healthy, independent aging in older individuals in the US and Australia is better captured by ASPREE's distinctive composite primary endpoint.
9	Rothwell et al. 2010 [52]	Randomized trials	To examine the long-term effect of aspirin in patients with colorectal cancer.	At least 75 mg of aspirin should be taken every day for several years to prevent the long-term incidence and mortality from colorectal cancer. The highest benefit was seen for proximal colon malignancies, which are not otherwise effectively prevented.